FinscoFinsco

BioLife Solutions (US.BLFS)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.BLFS · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion134.0%↑
ROE0.3%↑
Cash Conversion-41.4%→
D/E Ratio0.04↑
Gross Margin63.6%↓
US.BLFS (BioLife Solutions) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   134.0%    ↑
ROE                0.3%    ↑
Cash Conversion  -41.4%    →
D/E Ratio          0.04    ↑
Gross Margin      63.6%    ↓
Key Metrics
US.BLFS (BioLife Solutions) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 134.0% ↑
ROE 0.3% ↑
Cash Conversion -41.4% →
D/E Ratio 0.04 ↑
Gross Margin 63.6% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies